Literature DB >> 25447520

Up-regulation of p21(WAF1/CIP1) by miRNAs and its implications in bladder cancer cells.

Chenghe Wang1, Zhong Chen2, Qiangqiang Ge1, Junhui Hu1, Fan Li1, Jia Hu1, Hua Xu1, Zhangqun Ye1, Long-Cheng Li3.   

Abstract

We have previously reported that synthetic dsRNA can activate p21 expression by targeting the p21 promoter, thereby suppressing the proliferation of human bladder cancer cells. As complementarity between dsRNA and its target sequences is necessary for RNA activation, miRNAs may also trigger p21 expression through the same mechanism. Here, the expression levels of three miRNAs (miR-370, miR-1180 and miR-1236) decreased in bladder cancer tissues compared to healthy controls and the levels of these mRNAs positively correlated with p21 mRNA levels. The three miRNAs induced nuclear p21 expression through p21-promoter binding. Overexpression of the three miRNAs inhibited the proliferation of bladder cancer cells mainly by regulating p21. Therefore, these miRNAs could be candidates for anti-cancer drugs.
Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bladder cancer; Gene promoter; RNA activation; miRNA; p21

Mesh:

Substances:

Year:  2014        PMID: 25447520     DOI: 10.1016/j.febslet.2014.10.037

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  36 in total

1.  miRNA activation is an endogenous gene expression pathway.

Authors:  Luis M Vaschetto
Journal:  RNA Biol       Date:  2018-04-03       Impact factor: 4.652

2.  A new layer of degradation mechanism for PR-Set7/Set8 during cell cycle.

Authors:  Nana Zheng; Xiangpeng Dai; Zhiwei Wang; Wenyi Wei
Journal:  Cell Cycle       Date:  2016-09-20       Impact factor: 4.534

Review 3.  MicroRNAs: Key Players in Bladder Cancer.

Authors:  Qi Li; Helei Wang; Hourong Peng; Qiuping Huang; Ting Huyan; Qingsheng Huang; Hui Yang; Junling Shi
Journal:  Mol Diagn Ther       Date:  2019-10       Impact factor: 4.074

4.  Induction of alpha-methylacyl-CoA racemase by miR-138 via up-regulation of β-catenin in prostate cancer cells.

Authors:  Kati Erdmann; Knut Kaulke; Christiane Rieger; Manfred P Wirth; Susanne Fuessel
Journal:  J Cancer Res Clin Oncol       Date:  2017-07-24       Impact factor: 4.553

5.  Clinicopathologic and prognostic significance of p21 (Cip1/Waf1) expression in bladder cancer.

Authors:  Kun Tang; Chenghe Wang; Zhong Chen; Hua Xu; Zhangqun Ye
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 6.  Bladder Cancer-related microRNAs With In Vivo Efficacy in Preclinical Models.

Authors:  Ulrich H Weidle; Fabian Birzele
Journal:  Cancer Diagn Progn       Date:  2021-07-03

7.  Wnt7a activates canonical Wnt signaling, promotes bladder cancer cell invasion, and is suppressed by miR-370-3p.

Authors:  Xiaojing Huang; Hongwen Zhu; Zemin Gao; Junzun Li; Junlong Zhuang; Yu Dong; Bing Shen; Meiqian Li; Hu Zhou; Hongqian Guo; Ruimin Huang; Jun Yan
Journal:  J Biol Chem       Date:  2018-03-16       Impact factor: 5.157

8.  Promoter-associated endogenous and exogenous small RNAs suppress human bladder cancer cell metastasis by activating p21 (CIP1/WAF1) expression.

Authors:  Chenghe Wang; Qiangqiang Ge; Zhong Chen; Jia Hu; Fan Li; Zhangqun Ye
Journal:  Tumour Biol       Date:  2015-12-07

9.  S-phase kinase-associated protein 2 impairs the inhibitory effects of miR-1236-3p on bladder tumors.

Authors:  Qingsong Zhang; Shuo Miao; Chuanchang Li; Kai Cui; Qiangqiang Ge; Zhong Chen
Journal:  Am J Transl Res       Date:  2018-03-15       Impact factor: 4.060

10.  Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.

Authors:  Hui Guo; Dongfeng Zeng; Hui Zhang; Taylor Bell; Jun Yao; Yang Liu; Shengjian Huang; Carrie J Li; Elizabeth Lorence; Shouhao Zhou; Tiejun Gong; Changying Jiang; Makhdum Ahmed; Yixin Yao; Krystle J Nomie; Liang Zhang; Michael Wang
Journal:  Oncogene       Date:  2018-10-25       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.